Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Slide 52 Solid TresibaⓇ performance strengthens basal insulin market share in Japan Japanese basal value market shares TresibaⓇ NPH LevemirⓇ glargine U100 biosimilar glargine U100 - Novo Nordisk Japanese total insulin value market shares Eli Lilly - Sanofi glargine U300 NN Total Basal 80% 70% 60% 50% 40% 30% 20% 10% 0% Feb 2015 Source: IQVIA monthly MAT Feb, 2018 value figures changing diabetes 60% .51% 43% 40% 17% .17% 20% -14% 6% 2% 0% Feb 2018 Feb 2015 Source: IQVIA monthly MAT Feb, 2018 value figures 59% 24% 17% Feb 2018 novo nordisk

View entire presentation